跳至主要内容
临床试验/CTRI/2024/07/070458
CTRI/2024/07/070458尚未招募2 期

ow dose Oral Metronomic Cyclophosphamide and Etoposide combination in Recurrent/Refractory High Grade Endometrial Cancer, a Single Arm Phase 2 Study

Dr Bhoor Singh0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Histologically confirmed recurrent / refractory high grade endometrial cancer [endometroid/serous/carcinosarcoma/clear cell]
  • 2.One or more prior lines of therapy with at least one platinum based chemotherapeutic regimen, containing carboplatin or cisplatin with platinum free interval of less than 1 year.
  • 3.Written informed consent.
  • 4.ECOG PS 0-2
  • 5.Measurable disease with at least one target lesion which could be used for response evaluation as per RECIST 1.1 criteria
  • 6.Adequate organ function

排除标准

  • 1.Low grade [grade I/II] endometrial cancer
  • 2.Patient who are eligible for hormonal therapy
  • 3. Patients with recurrent carcinoma endometrium with platinum free interval of more than 1 year
  • 4.Chemotherapy naïve patient [adjuvant/metastatic setting]
  • 5.Patients who are eligible/affordable for immunotherapy

研究者

发起方
Dr Bhoor Singh

相似试验